
    
      Primary Objective:

      • Determine the proportion of patients with full donor T-cell chimerism at Day 28 following
      hematopoietic cell transplantation.

      Secondary Objectives:

        -  Determine the risk of disease progression, overall and event free survival, and
           non-relapse mortality, following treatment with TLI; ATG; and TBI.

        -  Determine the incidence of acute and chronic GVHD following treatment with TLI; ATG; and
           TBI.

      Exploratory Objectives:

      • Determine the changes in frequency of hematopoietic stem, progenitor, and mature cell
      subsets and the changes in cytokine milieu and cellular architecture in the bone marrow of
      patients receiving TLI compared to TLI+TBI.
    
  